Does RIGEL PHARMACEUTICALS INC have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores RIGEL PHARMACEUTICALS INC (RIGL) 55.2 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 99, returns on capital 8, balance-sheet safety 92, capital discipline 24.

How has RIGL's Moat Score changed over time?

The record logs 2 readings since Jul 17, 2026; the latest reads 55.2 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

RIGEL PHARMACEUTICALS INC

RIGL · Healthcare · $742.3M mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power99

Median gross margin 98.5% over 8y, very stable.

Returns on capital8

Median ROIC -100.9%, above the 9% hurdle in 22% of years.

Balance-sheet safety92

Net debt/EBITDA 0.1x, interest coverage 17x.

Capital discipline24

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale

No price data

Owner earnings (normalized): —
Est. intrinsic value / share: —
Recent price: $40.54
Discount to value: No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

Fundamentals

There's no normalized fundamentals series for RIGL yet — it appears once ingest has processed its filings.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale55.2 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — RIGL has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#96 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#94HIMS HIMS & HERS HEALTH, INC.55.8 out of 100, Shallow moatShallow moat
#95PLX PROTALIX BIOTHERAPEUTICS, INC.55.7 out of 100, Shallow moatShallow moat
#97KNSA Kiniksa Pharmaceuticals International, plc55.0 out of 100, Shallow moatShallow moat
#98PTCT PTC Therapeutics, Inc.54.8 out of 100, Shallow moatShallow moat

Compare RIGL with its nearest peers →All Healthcare companies on the Index →

Common questions about RIGL

Does RIGEL PHARMACEUTICALS INC have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores RIGEL PHARMACEUTICALS INC (RIGL) 55.2 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 99, returns on capital 8, balance-sheet safety 92, capital discipline 24.
How has RIGL's Moat Score changed over time?: The record logs 2 readings since Jul 17, 2026; the latest reads 55.2 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows RIGL’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/RIGL"
  width="340" height="150" style="border:0"
  title="RIGL Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell RIGL. See the disclaimer.